Colonial Trust Advisors Has $10.59 Million Position in Stryker Co. (NYSE:SYK)
Colonial Trust Advisors reduced its stake in Stryker Co. (NYSE:SYK) by 2.5% in Q4, holding 29,404 shares valued at approximately $10.59 million. Other institutional investors also adjusted their positions. Notably, Director Ronda E. Stryker sold over 201,000 shares, decreasing her ownership by 5.24%. Analysts maintain a "Moderate Buy" consensus on Stryker, with a target price of $421.90. The stock opened at $363.44, with a market cap of $138.72 billion and a recent EPS of $4.01, surpassing estimates.
Colonial Trust Advisors trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,404 shares of the medical technology company's stock after selling 760 shares during the quarter. Colonial Trust Advisors' holdings in Stryker were worth $10,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
- If You Could Only Hold 3 Investments for Life, Consider These
A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter worth about $25,000. Rakuten Securities Inc. boosted its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the fourth quarter valued at $30,000. BankPlus Trust Department purchased a new position in Stryker during the fourth quarter valued at $33,000. Finally, Activest Wealth Management purchased a new position in shares of Stryker in the 4th quarter worth about $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
- 3 Stocks Helping to Bring AI to Healthcare
A number of brokerages recently issued reports on SYK. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Needham & Company LLC reissued a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Canaccord Genuity Group increased their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a report on Thursday, January 30th. Finally, Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $421.90.
View Our Latest Stock Report on Stryker
Stryker Trading Up 7.7 %
- Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon
SYK opened at $363.44 on Thursday. The stock has a market capitalization of $138.72 billion, a P/E ratio of 46.84, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm's fifty day simple moving average is $377.27 and its 200 day simple moving average is $373.71. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.
Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio is 43.30%.
Stryker Profile
(Free Report)Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
- Five stocks we like better than Stryker
- Insider Buying Explained: What Investors Need to Know
- First Solar Stock: What's Fueling the Early April Rally?
- ETF Screener: Uses and Step-by-Step Guide
- Why Analysts Boosted United Airlines Stock Ahead of Earnings
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Stryker Right Now?
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
